Giocon Pharma Profile
Key Indicators
- Authorised Capital ₹ 1.50 Cr
as on 26-12-2024
- Paid Up Capital ₹ 1.32 Cr
as on 26-12-2024
- Company Age 28 Year, 11 Months
- Last Filing with ROC 31 Mar 2019
- Open Charges ₹ 5.00 M
as on 26-12-2024
- Revenue -96.31%
(FY 2019)
- Profit -2105.60%
(FY 2019)
- Ebitda -270.17%
(FY 2019)
- Net Worth -24.18%
(FY 2019)
- Total Assets 0.99%
(FY 2019)
About Giocon Pharma
The Corporate was formerly known as Ion Pharmaceuticals Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2019. It's a company limited by shares with an authorized capital of Rs 1.50 Cr and a paid-up capital of Rs 1.32 Cr.
The company currently has active open charges totaling ₹5.00 M.
Sankeerth Tallapragada, Ramprasadreddy Vennapusa, and Dattatreya Aradyula serve as directors at the Company.
- CIN/LLPIN
U24232AP1996PLC023127
- Company No.
023127
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
06 Feb 1996
- Date of AGM
30 Sep 2019
- Date of Balance Sheet
31 Mar 2019
- Listing Status
Unlisted
- ROC Code
Roc Vijayawada
Industry
Company Details
- Location
Visakhapatnam, Andhra Pradesh, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Giocon Pharma?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sankeerth Tallapragada  | Additional Director | 24-Dec-2019 | Current |
| Dattatreya Aradyula | Director | 31-Jul-2020 | Current |
| Ramprasadreddy Vennapusa | Additional Director | 24-Dec-2019 | Current |
Financial Performance of Giocon Pharma.
Giocon Pharma Limited, for the financial year ended 2019, experienced significant reduction in revenue, with a 96.31% decrease. The company also saw a substantial fall in profitability, with a 2105.6% decrease in profit. The company's net worth observed a substantial decline by a decrease of 24.18%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Giocon Pharma?
In 2019, Giocon Pharma had a promoter holding of 38.43% and a public holding of 61.57%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹0.50 Cr
₹0
Charges Breakdown by Lending Institutions
- City Union Bank Limited : 0.50 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 13 Feb 2015 | City Union Bank Limited | ₹5.00 M | Open |
How Many Employees Work at Giocon Pharma?
Unlock and access historical data on people associated with Giocon Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Giocon Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Giocon Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
